IDH2 and glioma: Consequently, Ag-881 was tested in a phase III clinical trial (INDIGO) in patients up/equal to 12 years of age and with residual or recurrent grade 2 Glioma who carried an IDH1 R132H/C/G/S/L or IDH2 mutation (115).